Colby Pharmaceutical Company

Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

Each year over 200,000 men are newly diagnosed with PCa in North America.

CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them.

Drugs for therapy-resitant solid cancers & hypoxic conditions

Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors

Colby drugs resore therapy-sensitivity or normoxia

Pipeline

Lead & Pipeline Drugs
CPC-100
CPC-200
CPC-300
CPC-410
Therapeutic Areas
Platform

Lead & Pipeline Drugs

Colby Pharmaceutical Company has developed a drug portfolio containing four small molecule pharma drug candidates targeting signal transduction pathways involved in the endogenous metabolic production of oxygen free radicals.